Key result
Higher fasting plasma glucose and CAD history linked to increased amygdalar metabolic activity.
Why the study?
The clinical and biochemical factors associated with amygdalar metabolic activity in subjects without malignant neoplasms were not well characterized.
What clinical and biochemical factors are associated with amygdalar metabolic activity in subjects without malignant neoplasms?
Cross-Sectional (n=346)
No
What clinical and biochemical factors are associated with amygdalar metabolic activity in subjects without malignant neoplasms?
Fasting plasma glucose and a history of coronary artery disease are independently associated with amygdalar metabolic activity, suggesting a link between metabolic/cardiovascular disease and stress-related brain activity.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in non-oncologic patients; hypothesis-generating for cardiometabolic influences on amygdalar activity.
F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) in 346 subjects without a history of malignant neoplasms. Univariate regression analysis revealed significant relationships between amygdalar metabolic activity and fasting plasma glucose (FPG), glycated hemoglobin, coronary artery disease (CAD) history, aspirin use, oral hypoglycemic agents (OHAs) use, and asymmetric dimethylarginine (ADMA). In multiple stepwise regression analysis, FPG and CAD history were independently associated with amygdalar metabolic activity. Moreover, in 36 patients with type 2 diabetes mellitus (T2DM), additional OHAs treatment significantly improved glycemic and metabolic parameters, and decreased ADMA concentrations. Baseline and Δpigment epithelium-derived factor (PEDF), a marker of insulin resistance, was a significant associate with Δamygdalar metabolic activity. Our study demonstrates that FPG and CAD history were independently associated with amygdalar metabolic activity in subjects without a history of malignant neoplasms. In T2DM patients, PEDF might regulate amygdala metabolic activity.
No takes yet. Share an insight, caveat, or question.
Tahara et al. (2025) conducted a cross-sectional in Cardiovascular disease risk (n=346). Fasting plasma glucose and coronary artery disease history was evaluated on Amygdalar metabolic activity evaluated by FDG-PET/CT (β 0.204, p=<0.001). Fasting plasma glucose and a history of coronary artery disease were independently associated with increased amygdalar metabolic activity in subjects without a history of malignant neoplasms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: